Trial · NCT05047523
Participant flow48
How many started, completed or left each group, period by period.
1 to 20 of 48
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Primary Evaluation Period (48 Weeks) | STARTED | Cohort 1: ALXN1840 | 15 | |
| Primary Evaluation Period (48 Weeks) | STARTED | Cohort 1: SoC Therapy | 16 | |
| Primary Evaluation Period (48 Weeks) | STARTED | Cohort 2: ALXN1840 | 4 | |
| Primary Evaluation Period (48 Weeks) | STARTED | Cohort 2: SoC Therapy | 5 | |
| Primary Evaluation Period (48 Weeks) | STARTED | ALXN1840/ALXN1840 | 0 | |
| Primary Evaluation Period (48 Weeks) | STARTED | SoC Therapy/ALXN1840 | 0 | |
| Primary Evaluation Period (48 Weeks) | Received at Least 1 Dose of Study Drug | Cohort 1: ALXN1840 | 15 | |
| Primary Evaluation Period (48 Weeks) | Received at Least 1 Dose of Study Drug | Cohort 1: SoC Therapy | 16 | |
| Primary Evaluation Period (48 Weeks) | Received at Least 1 Dose of Study Drug | Cohort 2: ALXN1840 | 4 | |
| Primary Evaluation Period (48 Weeks) | Received at Least 1 Dose of Study Drug | Cohort 2: SoC Therapy | 5 | |
| Primary Evaluation Period (48 Weeks) | Received at Least 1 Dose of Study Drug | ALXN1840/ALXN1840 | 0 | |
| Primary Evaluation Period (48 Weeks) | Received at Least 1 Dose of Study Drug | SoC Therapy/ALXN1840 | 0 | |
| Primary Evaluation Period (48 Weeks) | COMPLETED | Cohort 1: ALXN1840 | 12 | |
| Primary Evaluation Period (48 Weeks) | COMPLETED | Cohort 1: SoC Therapy | 11 | |
| Primary Evaluation Period (48 Weeks) | COMPLETED | Cohort 2: ALXN1840 | 0 | |
| Primary Evaluation Period (48 Weeks) | COMPLETED | Cohort 2: SoC Therapy | 1 | |
| Primary Evaluation Period (48 Weeks) | COMPLETED | ALXN1840/ALXN1840 | 0 | |
| Primary Evaluation Period (48 Weeks) | COMPLETED | SoC Therapy/ALXN1840 | 0 | |
| Primary Evaluation Period (48 Weeks) | NOT COMPLETED | Cohort 1: ALXN1840 | 3 | |
| Primary Evaluation Period (48 Weeks) | NOT COMPLETED | Cohort 1: SoC Therapy | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05047523/flow